Abstract:e21006 Background: Immunotherapy has brought a great revolution to treatment of patients with lung adenocarcinoma (LUAD). However, the infiltrating cells in the tumor microenvironment (TME) could influence immunotherapy outcomes. This study aimed to investigate the TME subtypes based on 50 immune, stromal, and stem cell types in TME. Methods: The xCell algorithm was used to infer the enrichment scores in TME. We performed the k-mean consensus clustering to identify TME subtypes for LUAD patients. The ESTIMATE, ABSOLUTE, LUMP, and CPE algorithms were used to compare tumor purity and immune infiltration of TME subtypes. The genomic mutations and copy number variants were also calculated by “maftools” R package and GISTIC 2.0. We established a neural network model, based on the TCGA dataset and verified it in GEO datasets by the Kaplan-Meier curve and Cox regression analyses, to prove the stability of TME subtypes. Using prophetic algorithm, ridge regression model was established to predict the sensitivity of drugs in all datasets. In addition, TIDE score and submap analyses were used to speculate the potential response of patients in immunotherapy. Results: In our study, 50 types of cells, including immune (including lymphocyte and myeloid cells), stem, and stromal cells in TME, were included for analysis. Based on cell scores, 504 LUAD patients were divided into four different subtypes (C1, C2, C3 and C4). In univariable Cox regression, the hazard ratio (HR) value of C2 vs. C1 was 2.066 (95%CI: 1.313 - 3.250), the HR value of C3 vs. C1 was 1.821 (95%CI: 1.067- 3.108), and that of C4 vs. C1 was 2.313 (95%CI: 1.461 - 3.662). Then, a neural network model was established (the area under the curves in the testing cohort: 0.911) to validate our conclusions in external sets and similar results were observed. Through pseudotime trajectory, we discovered there were potential connections among clusters from C1 to C4. The C2 and C3 were the intermediate forms of C1 and C4, and thus, the survival, immunological, and metabolic status of C2 and C3 may be intermediate between C1 and C4. By comparing the cell infiltration and immune gene expression of the four clusters, we found that C1 and C3 may have a similar immune phenotype which was opposed to that of C2 and C4. Meanwhile, the enrichment scores of cell proliferation-related pathways were progressively increased in the four clusters, which may be related to survival outcomes of them. We noticed that C1 harbored a unique EGFR mutation compared to other clusters, which may be sensitive to erlotinib. Patients of C4 had lower TIDE scores, which indicated that these patients may get higher benefits from immunotherapy. Conclusions: In conclusion, we identified four TME subtypes with distinct clinical outcomes and biological features, including tumor immunity, TME status, tumor mutations, and responses to chemotherapy and immunotherapy.

Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses

Identification of Immune-Related Gene Signature Predicting Survival in the Tumor Microenvironment of Lung Adenocarcinoma.

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma

Identification and validation for biological characteristics and prognosis of tumor microenvironment subtypes in patients with lung adenocarcinoma.

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma

A Robust Seven-Gene Signature Associated with Tumor Microenvironment to Predict Survival Outcomes of Patients with Stage III–IV Lung Adenocarcinoma

Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma.

Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma

Integration of Multiple Key Molecules in Lung Adenocarcinoma Identifies Prognostic and Immunotherapeutic Relevant Gene Signatures.

Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes

Immune Profile of the Tumor Microenvironment and the Identification of a Four-Gene Signature for Lung Adenocarcinoma

A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma

The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas

The Tumor Microenvironment in Gastrointestinal Adenocarcinomas Revealed a Prognostic and Immunotherapeutic Biomarker.

Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC)

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma

Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma

Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma

Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma

An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma